A carregar...
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threonin...
Na minha lista:
| Publicado no: | J Pers Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4263962/ https://ncbi.nlm.nih.gov/pubmed/25563355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm4030297 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|